Smartphone-based Saliva Testing and Self-monitoring of Blood Glucose Driving the Digital POCT Market

Mobility Ecosystem Holds Bold Promise to Expand Patients’ Access to Care

Smartphone-based devices and associated tools are becoming the ideal next-generation point-of-care testing (POCT) solutions for in vitro diagnostics. The global COVID-19 pandemic has led to frugal innovations in POCT. The World Health Organization (WHO) has endorsed POCT as the topmost research priority in response to the COVID-19 outbreak. Digital POCT platforms have spurred the market, demonstrating how the iterative nature of science can be leveraged to achieve WHO’s ASSURED criteria that define the paradigm of ideal point-of-care diagnostics and a key design principle.

The study focuses on the growth opportunities and strategic imperatives that are driving new diagnostic algorithms, massively boosted by COVID-19 and a matured diabetes market that is now well suited for remote diagnostics. The study assesses how current POCT platforms using smartphones for respiratory and metabolic diseases are being transformed in the new era of 5G, Internet of Things (IoT), artificial intelligence/machine learning, and alternate care sites.

The advent of alternate care sites, notably retail, indicates a future driven by digitally empowered patient and connected diagnostic tests. The dawn of 5G (cellular) with machine-based intelligence, data analytics, and IoT promises new ways to personalize diagnostic testing by reducing hospital visits and medical costs and by building evidence to assure the practicalities of precision diagnostics. Increased government funding, notably for respiratory tract infections, in the United States is setting the tone for testing at scale or consumerization in diagnostic testing.


Access Preview

* indicates mandatory fields